Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-20
2005-12-20
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S235800, C544S121000, C544S391000
Reexamination Certificate
active
06977258
ABSTRACT:
This invention is directed to acyl piperazine derivatives of formula (Ia):wherein R1a, R2, R3, R4, R5and R6are defined herein, which are useful as anti-inflammatory agents. This invention is also directed to other acyl piperazine derivatives, pharmaceutical compositions containing the compounds of the invention, and methods of using the compounds to treat inflammatory disorders in humans.
REFERENCES:
patent: 3324117 (1967-06-01), Schorr et al.
patent: 4294851 (1981-10-01), Metz et al.
patent: 4439606 (1984-03-01), Du et al.
patent: 4645525 (1987-02-01), Forster et al.
patent: 4859700 (1989-08-01), Lavielle et al.
patent: 4885299 (1989-12-01), Lavielle et al.
patent: 4970301 (1990-11-01), Rolland et al.
patent: 4987132 (1991-01-01), Mase et al.
patent: 5232923 (1993-08-01), Fukazawa et al.
patent: 5272175 (1993-12-01), Hansen, Jr. et al.
patent: 5280024 (1994-01-01), Bolland et al.
patent: 5389645 (1995-02-01), Hansen, Jr. et al.
patent: 5596000 (1997-01-01), Esser et al.
patent: 5668138 (1997-09-01), Baziard-Mouysset et al.
patent: 5691340 (1997-11-01), Baziard-Mouysset et al.
patent: 6518276 (2003-02-01), Arzeno et al.
patent: 6521619 (2003-02-01), Link et al.
patent: 6528509 (2003-03-01), Hale et al.
patent: 389 112 (1987-10-01), None
patent: 260089 (1987-05-01), None
patent: 0090202 (1983-03-01), None
patent: 0090203 (1983-03-01), None
patent: 0 190 685 (1986-01-01), None
patent: 0 284 632 (1987-03-01), None
patent: 0 252 422 (1987-07-01), None
patent: 0 319 412 (1988-12-01), None
patent: 0 333 522 (1989-03-01), None
patent: 0 372 410 (1989-12-01), None
patent: 0 655 442 (1994-11-01), None
patent: 7524 (1968-03-01), None
patent: 1 434 323 (1976-05-01), None
patent: WO 92/21361 (1992-12-01), None
patent: WO 95/01343 (1995-01-01), None
patent: WO 95/09159 (1995-04-01), None
patent: WO 96/34864 (1996-11-01), None
patent: WO 98/02151 (1998-01-01), None
patent: 87/2972 (1987-04-01), None
Trivedi et al. in Annual Reports in Medicinal Chemistry, vol. 35, p. 191-200 (2000).
Vadodaria et al., “Synthesis and Central Nervous System Depressant Activity of New Piperazine Derivatives and Related Compounds II”,J. Med Chem(1969) 12(5):860-865.
Hertz and Deghengi, “Effect of rat and beta-human interferons on hyperacute experimental allergic encephhaomyelitis in rats”,Agents Actions(1985) 16(5):397-403.
Rudick et al.,“In vivo effects on interferon beta-1a on immunosuppressive cytokines in multiple sclerosis”,Neurology(1998) 50:1294-1300.
Ruuls et al., “The length of treatment determines whether IFN-beta prevents or aggravates experimental autoimmune encephalomyelitis in Lewis rats”,J. Immunol. (1996) 157: 5721-5731.
Yu et al., “Interferon beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis”,J. Neuroimmunol. (1996) 64:91-100.
Rottman et al., Central Role of CCR1+ Cells in the Immunopathogenesis of Experimental Allergic Encephalomyelitis (EAE),FASEB(1999) 13(5):A666 Abstract 492-16.
Protiva et al.,Chemical Abstracts(1990), vol. 112, pp. 722-723, No. 158270d.
Eng et al., “Inflammation in EAE: Role of Chemokine/Cytokine Expression by Resident and Infiltrating Cells”,Neurochem. Res. (1996) 21:511-525.
Wells et al., “The Molecular Basis of the Chemokine/Chemokine Receptor Interaction—Scope for Design of Chemokine Antagonists”,Methods(1996) 10:126-134.
Leuschner, “N-Acyl substituted piperazines”,Chemical Abstracts(1974) 81:429-430, No. 136185u.
Okada and Shimabayashi, “Synthesis of N-(1-Methyl-2-piperazinoethyl)proprionanilides and 2-Alkoxy-6-[N-[1-methyl-2-2(4-phenylethylpiperazino)ethyl]-proprionamide]benzothiazoles”,Chem. Pharm. Bull. (1980). 28:3315-3322.
Ransohoff et al., “Chemokines in Immune-mediated Inflammation of the Central Nervous System”,Cytokine&Growth Factor Rev. (1996) 7:35-46.
Karpus and Ransohoff, “Cutting Edge Commentary: Chemokine Regulation of Experimental Autoimmune Encephalomyelitis: Temporal and Spatial Expression Patterns Govern Disease Pathogenesis”,J. Immunol. (1998) 161:2667-2671.
Karpus et al., “An Important Role for the Chemokine Macrophage Inflammatory Protein-1a in the Pathogenesis of the T Cell-Mediated Autoimmune Disease, Experimental Autoimmune Encephalomyelitis”,J. Immunol. (1995) 155:5003-5010.
Trebst et al., “CCR1+/CCR5+ Mononuclear Phagocytes Accumulate in the Central Nervous System of Patients with Multiple Sclerosis”,Am. J. Pathol. (2001) 159:1701-1710.
Rottman et al., “Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent”,Eur. J. Immunol. (2000) 30:2372-2377.
Liang et al., “Identification and Characterization of a Potent, Selective, and Orally Active Antagonist of the CC Chemokine Receptor-1”,J. Biol. Chem. (2000) 275:19000-19008.
Zikolova et al., “Analogs of N1-benzhydryl-N4-cinnamylpiperazine (oinnarizine) II N1-Substituted -N4-benzhydrylpiprazines”,Tr. Nauchnoizsled. Khim.-Farm. Inst. (1972), 8:59-6.
Ivanova et al., “Synthesis and pharmacological studies of a group of N-acylpiperazines”,Farmatsiya(Sofia) (1976), 26(4): 10-14.
Nikolova et al., “Preliminary pharmacological investigation of some piperazine derivatives”,Farmatsiya(Sofia) (1969), 19(2):31-37.
Zikolova et al., “Synthesis of piperazine derivatives VI Symmetric and asymmetric N-acylpiperazines with possible biological activity”,Tr. Nauchnoizsled. Khim.-Farm. Inst. (1972), 7:109-115.
Azize et al., “Thermal behavior and elastic properties of phospholipid bilayers under the effect of a synthetic flavonoid derivative, LEW-10”,Chemistry and Physics of Lipids(1992), 63:169-177.
Carceller et al., “(Pyridylcyanomethyl) piperazines as Orally Active PAF Antagonists”,J. Med. Chem(1992), 35:4118-4134.
Valenta et al., “Synthesis of 4-Methoxyphenoxyacetic and 3,4,5-Trimethoxyphenoxyacetic Acid Amides and Hydrazides as Potential Neurotropic and Cardiovascular Agents”,Collection Czechoslovak Chem. Commun. (1987), 52:3013-3023.
Valenta et al., “Basic Amides of 2,4,5-Trichlorophenoxyacetic, 2,4,6-Trimethylphenoxyacetic and 4-Bromo-3,5-Dimethylphenoxyacetic Acid and Some Related Compounds, Synthesis and Pharmacological Screening”,Collection Czechoslovak Chem. Commun. (1983), 48:1089-1096.
Protiva et al., “Basic Amides of 3,4,5-Trimethoxyphenoxy Acedic Acid: Synthesis and Pharmacology of Trimethophenoxamide and Analogues”,Collection Czechoslovak Chem. Commun. (1977), 42:3628-3642.
Petigara et al., Synthesis and Central Nervous System Depressant Activity of New Piperazine and Related Derivatives III,J. Med Chem(1969) 12(5):865-870.
Vadodaria et al., “Synthesis and Central Nervous System Depressant Activity of New Piperazine Derivatives and Related Compounds II”,J. Med Chem(1969) 12(5):860-865.
Hertz and Deghengi, “Effect of rat and beta-human interferons on hyperacute experimental allergic encephhaomyelitis in rats”,Agents Actions(1985) 16(5):397-403.
Rudick et al., “In vivo effects on interferon beta-1a on immunosuppressive cytokines in multiple sclerosis”,Neurology(1998) 50:1294-1300.
Ruuls et al., “The length of treatment determines whether IFN-beta prevents or aggravates experimental autoimmune encephalomyelitis in Lewis rats”,J. Immunol. (1996) 157: 5721-5731.
Bauman John G.
Buckman Brad O.
Ghannam Ameen F.
Hesselgesser Joseph E.
Horuk Richard
Berlex Inc.
Raymond Richard L.
Schering Aktiengesellschaft
LandOfFree
Piperazine derivatives and their use as anti-inflammatory... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperazine derivatives and their use as anti-inflammatory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperazine derivatives and their use as anti-inflammatory... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3501795